Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 5/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495312 | 0.91 | EGLN1 (0.65) | EGLN1GAAMGAMSIMGAM2 | |
| SCHEMBL1912783 | 0.89 | EGLN1 (0.59) | EGLN1EPHX1ACHEMMP2 | |
| SCHEMBL13552393 | 0.88 | EGLN1 (0.63) | EGLN1EPHX1GAAMGAMSI | |
| SCHEMBL9408944 | 0.87 | EGLN1 (0.57) | EGLN1EPHX1ACHE | |
| SCHEMBL11596790 | 0.86 | EGLN1 (0.61) | EGLN1EPHX1ACHEKDM4E | |
| SCHEMBL2032859 | 0.86 | EGLN1 (0.61) | EGLN1EPHX1ACHEKDM4E | |
| SCHEMBL2487820 | 0.85 | EPHX1 (0.57) | EGLN1EPHX1ACHE | |
| SCHEMBL15682714 | 0.85 | EPHX1 (0.57) | EGLN1EPHX1ACHE | |
| SCHEMBL11408936 | 0.85 | EPHX1 (0.57) | EGLN1EPHX1ACHE | |
| SCHEMBL28238203 | 0.84 | GAA (0.46) | EGLN1EPHX1GAAACHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117580831-A | GRK2 inhibitors and uses thereof | 索纳塔治疗公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | SONATA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | GRK2, GRK3, GRK1 | EGLN1 4519/4885EPHX1 4210/4885GAA 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.